Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dacomitinib and Osimertinib in EGFR-mutant NSCLC
NCT03810807Phase 1Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jan 2019
- Primary completion
- Dec 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of dacomitinib and osimertinib in non-small cell lung cancer (NSCLC), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Maximum Tolerated Dose at 1 year. Started Jan 2019; status: completed.
02
Drugs
dacomitinibosimertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03810807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03810807.